Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE VERY LOW (˜6 mg/IM) DOSE showed no clear difference in clinical response: mental state ‐ relapse ‐ medium term Relapse rate compared with FLUPENTHIXOL DECANOATE LOW DOSE (˜9 mg/IM) (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global impression ‐ no improvement ‐ medium term As defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ medium/long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review